Aquestive Therapeutics (NASDAQ: AQST) net income
Aquestive Therapeutics reported a net loss of $83.8m for fiscal 2025; in fiscal 2024 it reported a net loss of $44.1m. Earnings per share were −$0.78.
Aquestive Therapeutics's best year of the last 9 was fiscal 2023. It reported a loss in 9 of those 9 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$83.8m | — | −188.1% | −$0.78 |
| 2024 | −$44.1m | — | −76.7% | −$0.51 |
| 2023 | −$7.9m | — | −15.6% | −$0.13 |
| 2022 | −$54.4m | — | −114.1% | −$1.12 |
| 2021 | −$70.5m | — | −138.8% | −$1.85 |
| 2020 | −$55.8m | — | −121.7% | −$1.66 |
| 2019 | −$66.2m | — | −125.9% | — |
| 2018 | −$61.4m | — | −91.0% | — |
| 2017 | −$8.9m | — | −13.4% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Aquestive Therapeutics net income compared with its sector
By net income for its latest fiscal year, Aquestive Therapeutics ranks 322nd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Aquestive Therapeutics, −188.1%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 320th | LENZ Therapeutics | −$82.1m | −430.3% |
| 321st | Geron | −$83.5m | — |
| 322nd | Aquestive Therapeutics | −$83.8m | −188.1% |
| 323rd | Artiva Biotherapeutics | −$83.9m | — |
| 324th | Clover Health Investments | −$85.5m | −4.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Aquestive Therapeutics
- How much did Aquestive Therapeutics earn in fiscal 2025?
- Aquestive Therapeutics reported a net loss of $83.8m for fiscal 2025. In fiscal 2024 it reported a net loss of $44.1m.
- What are the earnings per share of Aquestive Therapeutics?
- They were −$0.78 in fiscal 2025, compared with −$0.51 in fiscal 2024.
- Where does Aquestive Therapeutics rank in its sector by net income?
- It ranks 322nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Aquestive Therapeutics come from?
- From the annual report (Form 10-K) that Aquestive Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Aquestive Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Aquestive Therapeutics: the Aquestive Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.